TL1A: A New Potential Target in the Treatment of Inflammatory Bowel Disease

Federica Furfaro, Ludovico Alfarone, Daniela Gilardi, Carmen Correale, Mariangela Allocca, Gionata Fiorino, Marjorie Argollo, Alessandra Zilli, Eirini Zacharopoulou, Laura Loy, Giulia Roda, Silvio Danese

Research output: Contribution to journalReview articlepeer-review


Inflammatory bowel diseases (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), are chronic inflammatory diseases of the gastrointestinal tract. In the last few years, the development of biological agents targeting cytokines and receptors involved in IBD pathogenesis has led to better outcomes and has improved the course of the disease. Despite their effectiveness, drugs such as tumor necrosis factor (TNF) inhibitors, anti-Interleukin-12/23 and anti-integrins, do not induce a response in about one-third of patients, and 40% of patients lose response over time. Therefore, more efficient therapies are required. Recent studies showed that TL1A (Tumor necrosis factor-like cytokine 1A) acts as a regulator of mucosal immunity and participates in immunological pathways involved in the IBD pathogenesis. In this review article, we analyze the role of TL1A as a new potential target therapy in IBD patients.

Original languageEnglish
Pages (from-to)760-769
Number of pages10
JournalCurrent Drug Targets
Issue number7
Publication statusPublished - 2021


  • Colitis, Ulcerative/drug therapy
  • Crohn Disease/drug therapy
  • Humans
  • Inflammatory Bowel Diseases/drug therapy
  • Tumor Necrosis Factor Ligand Superfamily Member 15/antagonists & inhibitors


Dive into the research topics of 'TL1A: A New Potential Target in the Treatment of Inflammatory Bowel Disease'. Together they form a unique fingerprint.

Cite this